Achilles Therapeutics plc

ACHL

US00449L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 14/05/2024 am IST			5-day change	1st Jan Change
0.8898 ^USD	-5.35%		+7.23%	+0.09%

08/05	Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/04	Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	MT

Achilles Therapeutics plc(NasdaqGS:ACHL) dropped from NASDAQ Biotechnology Index

December 16, 2022 at 10:30 am IST

Achilles Therapeutics plc has been dropped from NASDAQ Biotechnology Index.

Latest news about Achilles Therapeutics plc

Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Piper Sandler Downgrades Achilles Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $8	05/04	MT
Chardan Capital Adjusts Achilles Therapeutics Price Target to $6 From $11, Maintains Buy Rating	05/04	MT
ADRs Close Lower; Moatable Inc. Declines 33.3%	05/04	DJ
Syncona notes investee Achilles's annual loss narrows	04/04	AN
Achilles Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	04/04	CI
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04/04	CI
Achilles Therapeutics plc Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning	04/04	CI
BofA Securities Downgrades Achilles Therapeutics to Underperform From Buy, Price Target is $0.50	14/12	MT
Syncona notes investee company's quarterly loss	14/11	AN
Achilles Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Syncona's portfolio Achilles Therapeutics net loss narrows	04/23/04	AN
Achilles Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04	CI
Uncertain Investor Sentiment Weighs on American Depositary Receipts of European Equities	09/23/09	MT
Chardan Trims Price Target on Achilles Therapeutics to $11 From $12, Keeps Buy Rating	11/23/11	MT
Syncona say portfolio clinical company Achilles have widened losses	10/23/10	AN
Achilles Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Achilles Therapeutics plc Announces New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies Most Potent T Cell Antigens	10/23/10	CI
Achilles Therapeutics Receives Non-Compliance Notice From Nasdaq	26/23/26	MT
Biotech, Natural Resources Lead European Equities Lower in Wednesday Trading	19/23/19	MT
Bank Stock Recovery Supports American Depositary Receipts of European Equities	27/23/27	MT
Chardan Adjusts Price Target on Achilles Therapeutics to $12 From $17, Keeps Buy Rating	08/23/08	MT
Achilles Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	07/23/07	CI
China Reopening Prospects Lend Some Support to European Equities But Uncertain Outlook Weighs	28/22/28	MT
Achilles Therapeutics plc(NasdaqGS:ACHL) dropped from NASDAQ Biotechnology Index	16/22/16	CI

Chart Achilles Therapeutics plc

Duration

Period

More charts

Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.

Sector

Biotechnology & Medical Research

Calendar

25/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8898 USD

Average target price

5.333 USD

Spread / Average Target

+499.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACHILLES THERAPEUTICS PLC	+0.09%	3.86Cr
MODERNA, INC.	+26.37%	4.5TCr
IQVIA HOLDINGS INC.	-1.01%	4.26TCr
LONZA GROUP AG	+46.00%	4.18TCr
CELLTRION, INC.	-5.31%	2.9TCr
ICON PUBLIC LIMITED COMPANY	+9.34%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	1.9TCr
BIO-TECHNE CORPORATION	+6.23%	1.28TCr
MEDPACE HOLDINGS, INC.	+26.99%	1.21TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	1.18TCr

Other Biotechnology & Medical Research